Insulet Corporation reported significant financial growth in its latest quarterly results, with total revenue for the three months ended September 30, 2025, reaching $706.3 million, a 29.9% increase from $543.9 million in the same period last year. For the nine months ended September 30, 2025, revenue rose to $1.924 billion, up 30.5% from $1.474 billion in the prior year. The growth was primarily driven by increased sales volume of the Omnipod product line, particularly the Omnipod 5, which has seen strong adoption in both U.S. and international markets.
The company’s net income for the third quarter was $87.6 million, compared to $77.5 million in the same quarter of 2024, while net income for the nine-month period was $145.5 million, down from $317.6 million in the previous year. The decrease in net income for the nine months was attributed to a $123.9 million loss on extinguishment of debt related to the repurchase of convertible notes. Earnings per share for the third quarter were $1.24, up from $1.11 a year earlier, while diluted earnings per share were $1.24 compared to $1.08 in the prior year.
Operationally, Insulet has expanded its customer base, with U.S. revenue from Omnipod products increasing by 25.6% to $497.1 million in the third quarter, and international revenue rising by 46.5% to $202.1 million. The company has also launched Omnipod 5 in nine additional countries, enhancing its international presence. The total number of customers utilizing the Omnipod platform has grown, contributing to a recurring revenue model that is expected to drive future growth.
In terms of expenses, Insulet's cost of revenue for the third quarter was $196.2 million, representing 27.8% of total revenue, down from 30.7% in the same quarter last year, indicating improved gross margins. Research and development expenses increased by 40.6% to $77.2 million, reflecting the company's commitment to innovation and product development. Selling, general, and administrative expenses also rose by 34.7% to $315.2 million, driven by increased headcount and advertising costs to support the launch of Omnipod 5.
Looking ahead, Insulet anticipates continued revenue growth driven by the expanding adoption of Omnipod 5 and ongoing international market development. The company expects to maintain a gross margin above 71% for the full year 2025, supported by improved manufacturing efficiencies and pricing strategies. Insulet's strategic focus on enhancing its product offerings and expanding its market reach positions it well for sustained growth in the diabetes management sector.
About INSULET CORP
Insulet Corporation develops and manufactures tubeless, wearable insulin delivery systems, primarily through its Omnipod platform. The company offers automated insulin management devices for people with insulin-dependent diabetes, including type 1 and type 2. Its products enhance diabetes management by providing discreet, customizable, and connected insulin delivery solutions, serving global markets with a focus on improving patient outcomes and quality of life.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.